




Protein Optimization

SBT custom designs proteins for enhanced stability, function, and production. Our cutting-edge technology sets us apart from the companies chasing old school approaches like high throughput screening (HTS), antibody affinity maturation, and combinatorial libraries. With a focus on commercial value, we provide our customers with protein reagents having

- Improved Stability
- Improved Affinity
- Improved Production






Your Own Reagents—Only Better

SBT partners with other companies and government entities to bring the advantages of its technology platform to existing reagent sets. Generating new, optimized versions of key antibody reagents adds tremendous value through improved functionality and global cost savings. With the SBT advantage, our customers can:

- Eliminate cold chain storage/transport concerns
- Enhance their IP positioning
- Exclude *in vivo* and hybridoma production
- Experience reduced unit costs
- Extend product shelf life

Customized intelligent design, not rote brute force

SBT's technology platform combines proprietary bioinformatics, expression, and production systems. In-house algorithms, innovative laboratory techniques, and state-of-the-art equipment and facilities enable highly efficient translation of proteomic data to high quality protein optimized for the application at hand.



Examples of enhanced thermal and chemical stabilities of scFv reagents developed from customer-supplied sequences. (1) thermal shift assays; (2) thermal vs chemical unfolding transitions; (3) retention of functionality demonstrated by ELISA

StableBody Technologies, LLC


Cold Chain Free (CCFr): The forefront of Next Generation Stable Proteins

SBT is committed to becoming an industry leader for the stabilization and optimization of proteins, and *the* premier provider of antibody-derived cold chain free reagents (CCFr). Single chain variable fragments (scFv) are particularly suited to SBT's technology. These proteins have important advantages over traditional antibodies.

- Multiplied unit binding capacity
- Rapid development times
- Require little or no purified antigen or initial antibody.
- Can optimize for binding, stability *and* production properties
- Consistent, scalable, entirely *in vitro* production

In a matter of weeks, SBT can produce gram quantities of CCFr, recombinant scFv from a native antibody with enhanced binding and thermal and chemical stability.

A global perspective and appreciation of how reagents will be used lead to true product success. We recognize that for most applications, it's not *just* about optimizing binding. SBT's approach encompasses both functional design and production.



*Ribbon diagram of an scFv
(Plückthun laboratory, University of Zurich)*

Company Focus

SBT is a reagent company. We pride ourselves on delivering customized, quality products at an affordable price. Our platform technology has been applied to protein reagents used in fields ranging from national defense to environmental remediation. Our two largest active programs are high-impact and support our company slogan,

"Healthier living in a safer world."

Clinical Reagents Optimized scFv reagents are perfectly suited to the detection of biomarkers used to diagnose, categorize and treat disease. This is being applied to vascular mimicry pathways for cancer classification and therapy. Clinical methods employing SBT technology have advantages in cost, proprietary positioning and extended shelf life.

Biothreat Countermeasures SBT is working with the Department of Homeland Security to develop highly specific and sensitive reagents that can be used to rapidly detect and counteract biological threats in environmentally rugged conditions.

Design Process

The process begins with a thorough understanding of the context in which the reagent will be used. The customer and SBT jointly develop individualized optimization goals. Our team is made up of experts in pharmaceutical commercialization, systems integration, bioinformatics, protein expression systems, molecular biology, assay development, and project management to address the full range of product development needs.

For more information, please contact:

H. Rossiter Horn, R.Ph.
CEO/COO, StableBody Technologies, LLC
(608) 698-8445
hrhorn@stablebodytech.com

www.StablebodyTech.com